Issuu on Google+

Pharmaceutical Analytical Outsourcing Market - India to be a Key Destination for Analytical Services Government/Regulatory Support for Drug Discovery in India Government support in India for the development of the drug discovery and development market has been largely focused on the purchasing power parity (PPP) model. Unlike China, the government in India has encouraged private entrepreneurship by helping the private biotech and pharmaceutical companies in their projects through collaborative research, loans or grant-in-aid. The Department of Science and Technology leads the government initiatives for encouraging research and development R&D in the country, which has largely benefited the healthcare and pharmaceutical industry. The conceptualization, implementation and monitoring of the majority of the government’s initiatives has been handled by Council of Scientific and Industrial Research (CSIR). The department established several bodies, such as the Drug Development Promotion Board and the Technology Development Board, in order to provide funding for research projects across different sectors. These bodies have entered into collaborations with a number of drug discovery and development projects with Indian pharmaceutical companies. The agencies are also collaborating with various national level research institutes and universities across the country. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Pharmaceutical-Analytical-ServicesOutsourcing-in-India-Cost-Savings-Product-Quality-and-Shorter-Delivery-Times-areKeyDrivers&ReportType=Industry_Report&coreindustry=ALL&Title=Medical_Devices Business model analysis of Indian companies reveals that they have adopted the strategy of hiving off their R&D divisions into separate companies. One of the major reasons for the hive-off strategy is believed to be the possibility of attracting strategic investments in the high cost-burdened drug development sector. The hive-off strategy also helps the pharmaceutical companies to de-risk their generic businesses from the burden of R&D costs for new drugs. R&D costs also increase the tax burden on the parent company. An independent company can also help in attracting private equity/venture capital (PE/VC) funds and thereby protect the interests of risk-averse shareholders. It also helps the companies to get better valuations. GBI Research’s medical devices report, “Pharmaceutical Analytical Services Outsourcing in India: Cost Savings, Product Quality and Shorter Delivery Times are Key Drivers” provides key data, information and analysis on the pharmaceutical analytical services outsourcing in india. The report provides market landscape, competitive landscape and market trends information on the segments within the analytical services market. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews


the competitive landscape, services technology offerings. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Pharmaceutical-Analytical-ServicesOutsourcing-in-India-Cost-Savings-Product-Quality-and-Shorter-Delivery-Times-areKeyDrivers&ReportType=Industry_Report&coreindustry=ALL&Title=Medical_Devices Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@gbiresearch.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782


Pharmaceutical Analytical Outsourcing Market